Global Diabetic Nephropathy Market 2018-2022

Below are some of the key findings from the diabetic nephropathy market research report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global diabetic nephropathy industry overview

In the past years, there has been a significant increase in diabetic nephropathy among diabetic patients. The factors associated with the rise of incidence of diabetic nephropathy are hypercholesterolemia, hypertension and obesity. In addition, the lack of awareness and the use of alternative medical practices is leading to an increase in the incidence of diabetic nephropathy, especially in developing countries. This offers a huge opportunity for manufacturers to develop new and effective drugs which will boost the diabetic nephropathy market growth.

The rise in the incidence of diabetes is one of the key trends impacting the diabetic nephropathy market. The incidence and prevalence of diabetes have been increasing significantly over the years, resulting in the occurrence of chronic kidney diseases in patients. Many initiatives are underway by organizations such as the World Health Organization and the International Diabetes Federation to increase awareness about diabetes and its associated conditions. This will impact the growth of the diabetic nephropathy market during the forecast period.

Top diabetic nephropathy companies covered in this market research report

The diabetic nephropathy market is highly concentrated. By offering a complete analysis of the market's competitive landscape and with information on the products offered by the companies, this diabetic nephropathy industry analysis report will aid clients to identify new growth opportunities and design new growth strategies.

The report offers a complete analysis of various companies including:

• AstraZeneca
• Merck
• Sanofi

Diabetic nephropathy market segmentation based on geographic regions

• Americas
• APAC
• EMEA

With a complete study of the growth opportunities for the companies, the Americas region will account for the highest diabetic nephropathy market share throughout the forecast period. The growth in this region is attributable to the increase in the prevalence of type 1 and type 2 diabetes mellitus and the ongoing R&D to treat diabetic nephropathy in the Americas.

Diabetic nephropathy market segmentation based on drug class

• ARBs
• ACE inhibitors
• Others

The ARBs segment will account for the highest incremental growth in the diabetic nephropathy market. Additionally, the report also provides an accurate prediction of the contribution of all the various segments to the growth of the diabetic nephropathy market size.

Key highlights of the global diabetic nephropathy market for the forecast years 2018-2022:

• CAGR of the market during the forecast period 2018-2022
• Detailed information on factors that will accelerate the growth of the diabetic nephropathy market during the next five years
• Precise estimation of the global diabetic nephropathy market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the diabetic nephropathy industry across the Americas, APAC and EMEA
• A thorough analysis of the market's competitive landscape and detailed information on several vendors
• Comprehensive details on the factors that will challenge the growth of diabetic nephropathy companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch